Published in BMC Neurosci on August 06, 2009
Over a century of neuron culture: from the hanging drop to microfluidic devices. Yale J Biol Med (2012) 0.97
Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human Na(V)1.1 mutation. J Neurosci (2014) 0.95
A new role for interferon gamma in neural stem/precursor cell dysregulation. Mol Neurodegener (2011) 0.90
Phosphorylation of p27Kip1 at Thr187 by cyclin-dependent kinase 5 modulates neural stem cell differentiation. Mol Biol Cell (2010) 0.87
A voltage-sensitive dye-based assay for the identification of differentiated neurons derived from embryonic neural stem cell cultures. PLoS One (2010) 0.85
Intrinsically active and pacemaker neurons in pluripotent stem cell-derived neuronal populations. Stem Cell Reports (2014) 0.85
In vitro neuronal network activity in NMDA receptor encephalitis. BMC Neurosci (2013) 0.80
Species-dependent differences of embryonic stem cell-derived neural stem cells after Interferon gamma treatment. Front Cell Neurosci (2012) 0.76
Characterisation of neurons derived from a cortical human neural stem cell line CTX0E16. Stem Cell Res Ther (2015) 0.75
The microenvironment of embryoid bodies modulated the commitment to neural lineage postcryopreservation. Tissue Eng Part C Methods (2014) 0.75
Simulation of developing human neuronal cell networks. Biomed Eng Online (2016) 0.75
Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro. Front Cell Neurosci (2016) 0.75
Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol (2003) 9.41
The cell biology of neurogenesis. Nat Rev Mol Cell Biol (2005) 9.35
Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol (2005) 9.12
Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev (2008) 5.34
Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech Dev (1998) 5.21
Embryonic stem cells express neuronal properties in vitro. Dev Biol (1995) 5.03
Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev (1996) 4.61
Directed differentiation of telencephalic precursors from embryonic stem cells. Nat Neurosci (2005) 4.34
Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci (1999) 3.61
Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech Dev (1996) 3.45
An extremely rich repertoire of bursting patterns during the development of cortical cultures. BMC Neurosci (2006) 3.29
Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J Neurosci (2007) 3.25
Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci (2004) 3.11
Notch promotes neural lineage entry by pluripotent embryonic stem cells. PLoS Biol (2006) 2.91
Glutamate transporter GLAST is expressed in the radial glia-astrocyte lineage of developing mouse spinal cord. J Neurosci (1997) 1.84
Dissociated cortical networks show spontaneously correlated activity patterns during in vitro development. Brain Res (2006) 1.83
Spontaneous periodic synchronized bursting during formation of mature patterns of connections in cortical cultures. Neurosci Lett (1996) 1.83
A neuron-silicon junction: a Retzius cell of the leech on an insulated-gate field-effect transistor. Science (1991) 1.74
Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem Cells (2008) 1.67
Longterm stability and developmental changes in spontaneous network burst firing patterns in dissociated rat cerebral cortex cell cultures on multielectrode arrays. Neurosci Lett (2004) 1.52
Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. Glia (2007) 1.51
Transplanted astrocytes derived from BMP- or CNTF-treated glial-restricted precursors have opposite effects on recovery and allodynia after spinal cord injury. J Biol (2008) 1.36
Induction of neurogenesis in nonconventional neurogenic regions of the adult central nervous system by niche astrocyte-produced signals. Stem Cells (2008) 1.32
Temporally restricted substrate interactions direct fate and specification of neural precursors derived from embryonic stem cells. Proc Natl Acad Sci U S A (2006) 1.20
Low-density neuronal networks cultured using patterned poly-l-lysine on microelectrode arrays. J Neurosci Methods (2006) 1.18
Single-neuron discharge properties and network activity in dissociated cultures of neocortex. J Neurophysiol (2004) 1.07
Development and differentiation of neural rosettes derived from human embryonic stem cells. Stem Cell Rev (2006) 1.06
Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol (2007) 1.02
Spontaneous neuronal firing patterns in fetal rat cortical networks during development in vitro: a quantitative analysis. Exp Brain Res (1987) 0.98
Electrical and neurotransmitter activity of mature neurons derived from mouse embryonic stem cells by Sox-1 lineage selection and directed differentiation. Eur J Neurosci (2004) 0.97
Embryonic stem cell-derived neuronally committed precursor cells with reduced teratoma formation after transplantation into the lesioned adult mouse brain. Stem Cells (2006) 0.97
Cryopreserved rat cortical cells develop functional neuronal networks on microelectrode arrays. J Neurosci Methods (2003) 0.94
Extracellular potentials in low-density dissociated neuronal cultures. J Neurosci Methods (2002) 0.92
Humoral and contact interactions in astroglia/stem cell co-cultures in the course of glia-induced neurogenesis. Glia (2005) 0.91
Embryonic stem cell-derived neurons form functional networks in vitro. Stem Cells (2006) 0.91
Neuronal network morphology and electrophysiologyof hippocampal neurons cultured on surface-treated multielectrode arrays. IEEE Trans Biomed Eng (2007) 0.88
Reconstruction of neural tube-like structures in vitro from primary neural precursor cells. Proc Natl Acad Sci U S A (1993) 0.88
Analytical characterization of spontaneous firing in networks of developing rat cultured cortical neurons. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 0.83
Glutamate-synthesizing enzymes in GABAergic neurons of the neocortex: a double immunofluorescence study in the rat. Neuroscience (1994) 0.82
Immunohistochemical localization of the vesicular glutamate transporter VGLUT2 in the developing and adult mouse claustrum. J Chem Neuroanat (2006) 0.82
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Guillain-Barré syndrome. N Engl J Med (2012) 6.28
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol (2010) 3.26
Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet (2003) 3.22
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07
Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 2.45
Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis (2010) 2.32
New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci (2002) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Symptomatic acute occlusion of the internal carotid artery: reappraisal of urgent vascular reconstruction based on current stroke imaging. J Vasc Surg (2008) 2.11
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood (2008) 2.01
Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain (2005) 1.92
Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol (2012) 1.84
Chronic inflammatory demyelinating polyneuropathy. N Engl J Med (2005) 1.79
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 1.69
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry (2012) 1.66
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci (2003) 1.65
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke (2004) 1.58
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology (2013) 1.56
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol (2006) 1.54
Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E epsilon4 allele. Arch Neurol (2003) 1.48
Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 1.47
Towards individualised multiple-sclerosis therapy. Lancet Neurol (2005) 1.46
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol (2009) 1.42
Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2005) 1.40
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother (2012) 1.40
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol (2003) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
A novel approach to describe a U1 snRNA binding site. Nucleic Acids Res (2003) 1.35
Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol (2007) 1.34
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain (2006) 1.29
Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol (2009) 1.28
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol (2013) 1.27
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation. Ann Neurol (2005) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs (2008) 1.25
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
In vivo MRI of brain inflammation in human ischaemic stroke. Brain (2004) 1.24
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. Ann Neurol (2009) 1.24
Animal models of multiple sclerosis--potentials and limitations. Prog Neurobiol (2010) 1.23
Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis (2009) 1.22
Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol (2003) 1.22
The complex world of oligodendroglial differentiation inhibitors. Ann Neurol (2011) 1.19
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol (2006) 1.17
New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol (2009) 1.15
Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2. J Cancer Res Clin Oncol (2010) 1.14
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 1.13
Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol (2002) 1.12
Development of brain infarct volume as assessed by magnetic resonance imaging (MRI): follow-up of diffusion-weighted MRI lesions. J Magn Reson Imaging (2004) 1.12
Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2009) 1.12
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol (2005) 1.10
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol (2007) 1.09
Diagnostics of pathogenic splicing mutations: does bioinformatics cover all bases? Front Biosci (2008) 1.09
Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain (2006) 1.09
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler (2012) 1.09
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve (2004) 1.09
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain (2002) 1.08
Viral load determines the B-cell response in the cerebrospinal fluid during human immunodeficiency virus infection. Ann Neurol (2007) 1.08
Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci (2010) 1.07
Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle Nerve (2013) 1.06
Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol (2011) 1.06
Store-operated calcium entry modulates neuronal network activity in a model of chronic epilepsy. Exp Neurol (2011) 1.05
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol (2013) 1.04
Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke (2007) 1.03
Immune circuitry in the peripheral nervous system. Curr Opin Neurol (2006) 1.03
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol (2007) 1.02